Development of novel pan-inhibitors of the androgen receptor variants as effective therapeutics for castration-resistant prostate cancer
Development of novel pan-inhibitors of the androgen receptor variants as effective therapeutics for castration-resistant prostate cancer
开发雄激素受体变体的新型泛抑制剂作为去势抵抗性前列腺癌的有效疗法
批准号：
325168
负责人：
Wu Jian Hui
金额：
$11.66万
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2015
资助国家：
加拿大
项目状态：
已结题
起止时间：
2015-02-01 至 2016-02-01
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Current treatment strategy for advanced prostate cancer is to suppress the androgen receptor (AR) signaling by castration and antiandrogens. Despite of initial response, lethal 'castration-resistant' prostate cancer (CRPC) arises as a result of AR reactiv
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Repurposing of FDA-approved drugs as novel therapeutics for COVID-19
-
批准号：422708
-
项目类别：Operating Grants
-
资助金额：$34.82万
-
财政年份：2020
-
负责人：Wu Jian Hui
-
依托单位：
Novel bifunctional antiandrogens that suppress oncogenic activation of the androgen receptor in castration-resistant prostate cancer
-
批准号：206036
-
项目类别：Operating Grants
-
资助金额：$11.64万
-
财政年份：2010
-
负责人：Wu Jian Hui
-
依托单位：
Chemical inhibitors of androgen receptor splice variants lacking the ligand-binding domain as novel agents for castration-resistant prostate cancer
-
批准号：212165
-
项目类别：Operating Grants
-
资助金额：$26.65万
-
财政年份：2010
-
负责人：Wu Jian Hui
-
依托单位：
海外基金
